Alongside a global shortage of donor organs for transplantation there is an emergent need to extend transplant availability and for regenerative therapies to restore organ function, increase quality and length of life and reduce healthcare costs.
Videregen’s decellularisation technology, is a proprietary methodology which employs a combination of detergents and enzymatic solutions to bath and perfuse biological tissues. This gentle process specifically targets and removes cells and associated DNA, which would otherwise cause an unwanted immunological response once implanted within the patient.
The resulting cell-free extra cellular matrix or scaffold, retains all those integral, compositional structures such as collagen, elastin and glycosaminoglycans which provide an inherently natural “cell friendly” environment. Upon re-seeding with the patients’ own cells this structure readily facilitates cellular proliferation and differentiation.
Re-seeding of the organ scaffold with autologous cells, reduces the risk of organ rejection and removes the requirement for expensive immunosuppressant (anti-rejection) drugs that can have detrimental side effects on the patient and organ.
Natural biologic scaffolds have sufficient structural integrity to function immediately on implantation, which in the case of the trachea, provides a naturally/fully formed open airway. The structure and composition also enables natural remodelling and integration, which is particularly important for children as the new organ can develop in a manner consistent with the patients’ normal growth and tissue turnover. These characteristics help to distinguish natural scaffolds from those that are made from a synthetic material.
Whilst synthetic matrices can be biocompatible and provide structural performance and functionality, the body is unable to remodel these structures and over time this potentially leads to a deterioration in functional performance. Initially focused on diseases of the trachea, bowel and liver, Videregen aims to develop the world’s first commercially available organ replacements for these conditions, reducing healthcare costs and improving patients’ quality and length of life.